ArticleVaccine2007
Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 75 citations in OpenAlex.
- Trial
- Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy.Frontiers in microbiology · 2026Review
- Review
- Research progress on emulsion vaccine adjuvants.Heliyon · 2024Review
- Evaluation of a Novel Multi-Epitope Peptide Vaccine Candidate from LACK, LeIF, GP63, SMT Antigens ofArchives of Razi Institute · 2022Article
- Homology Modeling,Frontiers in cellular and infection microbiology · 2022Article
- A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.Medical microbiology and immunology · 2020Article
- Sterol methyltransferase is required for optimal mitochondrial function and virulence in Leishmania major.Molecular microbiology · 2019Article
- Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice.Scientific reports · 2018Article
- Combined Strategies to Improve the Expression of Recombinant Sterol C24-Methyltransferase from Leishmania braziliensis in E. coli.Molecular biotechnology · 2018Article
- Extracellular Expression in Aspergillus niger of an Antibody Fused to Leishmania sp. Antigens.Current microbiology · 2018Article
- Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.PLoS neglected tropical diseases · 2017Article
- A Computational Methodology to Overcome the Challenges Associated With the Search for Specific Enzyme Targets to Develop Drugs AgainstBioinformatics and biology insights · 2017Article
- A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.NPJ vaccines · 2017Article
- Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.Vaccine · 2016Article
- Possibilities and challenges for developing a successful vaccine for leishmaniasis.Parasites & vectors · 2016Review
- From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.Clinical & translational immunology · 2015Article
- Structure and dynamics studies of sterol 24-C-methyltransferase with mechanism based inactivators for the disruption of ergosterol biosynthesis.Molecular biology reports · 2014Article
- Vaccines to prevent leishmaniasis.Clinical & translational immunology · 2014Review
- Development of Leishmania vaccines: predicting the future from past and present experience.Journal of biomedical research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We present here the identification and characterization of Leishmania sterol 24-c-methyltransferase (SMT), as well as data on protection of mice immunized with this Ag formulated in MPL-SE. Serological evaluation revealed that SMT is recognized by VL patients. C57BL/6 mice immunized with this vaccine candidate plus MPL-SE showed Ag-specific Th1 immune responses characterized by robust production of IFN-gamma upon specific Ag re-exposure in vitro. Upon challenge with L. infantum, mice immunized with SMT plus MPL-SE showed significant lower parasite burdens in both spleens and livers compared with non-immunized mice or mice injected with adjuvant alone. The results indicate that SMT/MPL-SE can be an effective vaccine candidate for use against VL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.